Navigation Links
Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery

, MD, of Hoersholm Hospital, University of Copenhagen, Denmark, commented: "The RECORD3 results are exciting, as they indicate that rivaroxaban may better meet the needs of many patients undergoing orthopaedic surgery. It’s an important step for this category that a once-daily, oral medication has demonstrated better efficacy in preventing VTE than the current standard of care, while also displaying a promising safety profile. In addition, it is important to note that symptomatic VTE, a secondary endpoint of the study, showed results in favour of rivaroxaban."

Detailed Study Results RECORD3 is a 2,531-patient, Phase III, double-blind trial that assessed the safety and efficacy of 10 mg oral, once-daily rivaroxaban started 6-8 hours after surgery versus 40 mg subcutaneous, once-daily enoxaparin started the evening before surgery in elective total knee replacement (TKR) surgery. Both regimens were continued for 10-14 days. The primary efficacy endpoint of the study was the composite of DVT, as diagnosed by mandatory venography, non-fatal PE and all-cause mortality. The primary safety endpoint was major bleeding. Results showed that DVT, non-fatal PE and death occurred in 9.6% (79/824) of patients receiving rivaroxaban versus 18.9% (166/878) of patients receiving enoxaparin (RRR 49%; p < 0.001).

Major VTE (the composite of proximal DVT, non-fatal PE and VTE-related death) - the main secondary efficacy endpoint of the study - occurred in 1.0% of the rivaroxaban-treated group and in 2.6% of the enoxaparin-treated group. The difference was statistically significant (p=0.01) in favour of rivaroxaban, with an RRR of 62%.

A reduction was also demonstrated in symptomatic VTE, a pre-specified additional secondary endpoint in the study. Symptomatic VTE occurred in 1.0% of patients who received rivaroxaban, compared to 2.7% of those in the enoxaparin comparator group, resulting in an RRR of 64%.

In the rivaroxaban and enoxaparin groups, major bl
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
Post Your Comments:
(Date:10/2/2014)... Mass. , Oct. 2, 2014  Alere Inc. (NYSE: ... announced today that the new E. HISTOLYTICA QUIK CHEK™ ... parasite, has received CE Mark for sale in international markets ... test is developed and manufactured by TECHLAB ® Inc. ... that infects an estimated 50 million people worldwide. Infected individuals ...
(Date:10/2/2014)... WOONSOCKET, R.I. , Oct. 2, 2014 ... Health Research Institute entitled, " Adherence: why it,s so ... reviews the Company,s key research findings on medication adherence ... five to 15 percent through new interventions by 2017. ... Institute has been focused on building the body of ...
(Date:10/2/2014)... , Oct. 2, 2014  MinuteClinic, the largest and fastest ... States , has opened its first walk-in clinics in the ... stores in Corpus Christi and ... Corpus Christi in December. The clinics are ... nationwide in 2014. With the Corpus Christi -area ...
Breaking Medicine Technology:Entamoeba histolytica Rapid Test Receives CE Mark 2CVS Health Insights Report Tackles Complex Issue of Medication Adherence 2CVS Health Insights Report Tackles Complex Issue of Medication Adherence 3First MinuteClinic Walk-in Medical Clinics Open in Corpus Christi 2First MinuteClinic Walk-in Medical Clinics Open in Corpus Christi 3
... Attorneys representing a group of U.S. citizens suffering from ... thalidomide have filed a lawsuit in federal court to compel ... drug was widely distributed in the United States. ... to a number of Freedom of Information Act (FOIA) requests ...
... of brand drug "copay coupon" promotions, which lure insured ... costs by $1.8 billion in Pennsylvania over the next ... to new research from Visante and released by the ... of these promotions by state and local government workers ...
Cached Medicine Technology:Hagens Berman: Patients Seek to Force FDA to Release Records Showing US Distribution of Thalidomide 2Hagens Berman: Patients Seek to Force FDA to Release Records Showing US Distribution of Thalidomide 3Brand Drug 'Copay Coupons' Undermine Generics, Raise Health Costs by $1.8 Billion in Pennsylvania 2
(Date:10/2/2014)... October 02, 2014 The Business ... 2014 BIG Awards for Business program. The BIG ... with a proprietary judging process scored by well-known ... globe. , “The winners this year epitomize what ... Managing Director of the Business Intelligence Group. “The ...
(Date:10/2/2014)... October 02, 2014 BamboofloorChina.com is a ... products have won great appreciation from the global customers ... working hard to make more excellent items. All its ... to help all clients. , The company has ... to its website. Furthermore, the company’s marketing specialist ...
(Date:10/2/2014)... Maureen Salamon HealthDay Reporter ... Middle-aged women with a neurotic personality style and prolonged ... disease, new research suggests. Tracking 800 women over ... were most anxious, jealous and moody -- which they ... double the risk of developing Alzheimer,s compared to women ...
(Date:10/2/2014)... Oct. 1, 2014 (HealthDay News) -- Genes may interact with ... study suggests. The genetic risk occurs in about 13 ... The finding could help these people reduce their heart disease ... diet and stress management, the Duke University researchers said. ... and found a strong link between variations in the EBF1 ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. ... highway may raise your risk for high blood pressure, a ... those who lived within 109 yards of a busy road ... pressure than women living at least half a mile away, ... the importance of our physical environment on our health and ...
Breaking Medicine News(10 mins):Health News:Innovation Dominant Theme among 2014 Big Awards for Business Winners and Finalists 2Health News:High Quality Bamboo Panels Online At BamboofloorChina.com 2Health News:Jealous, Moody Women May Face Higher Alzheimer's Risk, Study Says 2Health News:Jealous, Moody Women May Face Higher Alzheimer's Risk, Study Says 3Health News:Genes May Make Some More Prone to Heart Disease When Under Stress 2Health News:Living Near a Highway May Be Bad for Your Blood Pressure 2Health News:Living Near a Highway May Be Bad for Your Blood Pressure 3
... U.S. Senate to vote soon on legislation that ... Minnesota, WASHINGTON, July 9 Seniors across ... Medicare Advantage program in,legislation being considered in the ... million from the Medicare Advantage program in,Minnesota alone ...
... support medical care for the uninsured, human,services, and ... Blue Cross and Blue Shield,of Illinois (BCBSIL) ... in Illinois. In line with its mission, "to ... communities through accessible,cost-effective, quality health care," BCBSIL,s giving ...
... the University of Alabama at Birmingham (UAB) have been ... The project is a national consortium of cutting-edge hospitals ... for patients with a kind of malignant brain tumor ... consortium, UAB will serve as the only research site ...
... Fans Can ,Start Their Engines, and Nominate Now at ... ... trusted brands,for indigestion and heartburn relief, is launching a nationwide search for,one ... 500 Sprint,Cup Series race at Martinsville Speedway in Martinsville, Va. on October,19, ...
... Daniel Von Hoff, a member of President ... in-depth look at "The Complete Phase Ib," ... rapid accrual rates, substantial economies of scale, ... patients, and improved therapeutic benefits. The ...
... ARLINGTON, Va., July 9 The HealthCentral,Network, ... new online medical and peer-to-peer resource,committed to ... about,drugs, surgeries and nutrition, along with offering ... Three expert writers, University of Pennsylvania clinical ...
Cached Medicine News:Health News:Minnesota Seniors Speak Out Against Medicare Advantage Cuts 2Health News:Blue Cross and Blue Shield of Illinois Gives $960,000 in Charitable Donations 2Health News:Blue Cross and Blue Shield of Illinois Gives $960,000 in Charitable Donations 3Health News:UAB joins elite brain cancer research group 2Health News:TUMS Announces Nationwide Search for Grand Marshal at TUMS QuikPak 500 2Health News:Dr. Daniel Von Hoff Discusses "The Complete Phase Ib," A Clinical Trial Design Offering Faster Drug Development, Economies of Scale and Improved Therapeutic Benefit 2Health News:Dr. Daniel Von Hoff Discusses "The Complete Phase Ib," A Clinical Trial Design Offering Faster Drug Development, Economies of Scale and Improved Therapeutic Benefit 3Health News:Responding to Increased Incidence of Obesity and Associated Health Issues, The HealthCentral Network Launches Site to Support those Struggling with Weight 2
This double-up gel dryer system, 100-120 V, includes 2 Model 583 gel dryers, HydroTech™ vacuum pump, and double-up rack....
... GelAir™ drying system utilizes a hot air drying ... dried on a clear cellophane support for easy ... a smooth, flat assembly surface for the drying ... frames at once. This 115 V, 60 Hz ...
... dryer is an electrophoresis gel vacuum dryer that ... dries these gels onto cellophane or filter paper ... elements which heat gels from above. The drying ... V unit includes power cord, porous gel support, ...
... The PRO6000 power supply ... Thermo's power supply product offering. ... proteomic and genomic electrophoresis. This ... to proteomic applications such as ...
Medicine Products: